Publication | Open Access

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Surgical OncologyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyPhase 3Tremelimumab Versus Chemotherapy